A bendamustine resistance gene signature in diffuse large B-cell lymphoma and multiple myeloma

Abstract

Aim: Bendamustine is primarily used for treatment of indolent lymphomas but has shown efficacy in some patients with diffuse large B-cell lymphoma (DLBCL) and multiple myeloma (MM). Molecular-based patient stratification for identification of resistant patients, who will benefit from alternative treatments, is important. The aim of this study was to develop a resistance gene signature (REGS) from bendamustine dose-response assays in cultures of DLBCL and MM cell lines, enabling prediction of bendamustine response in DLBCL and MM patients.

Methods: Bendamustine response was determined in 14 DLBCL and 11 MM cell lines. Using baseline gene expression profiles and degree of growth inhibition after bendamustine exposure, a bendamustine REGS was developed and examined for the risk stratification potential in DLBCL (n = 971) and MM (n = 1,126) patients divided into prognostic subtypes.

Results: Bendamustine resistance significantly correlated with resistance to cyclophosphamide in DLBCL and melphalan in MM cell lines. The bendamustine REGS showed significantly lower bendamustine resistance probabilities in DLBCL patients with GCB subtype tumors and in tumors of the differentiation dependent centrocyte and plasmablast subtypes. In MM patients, pre-BII classified tumors displayed high bendamustine resistance probabilities and the plasma cell subtype had lower bendamustine resistance probability than memory cells. Furthermore, tumors belonging to the 4p14, MAF, and D2 TC subclasses consistently displayed high bendamustine resistance probabilities.

Conclusion: Significant differences in predicted response to bendamustine were found in molecular subtypes of DLBCL and MM, encouraging validation in prospective bendamustine-treated cohorts with available gene expression profiles and follow-up data.

Keywords

Bendamustine / diffuse large B-cell lymphoma / multiple myeloma / resistance gene signature

References

[1] Gandhi V.Bendamustine in B-cell malignancies: the new 46-year-old kid on the block..Clin Cancer Res2009;15:7456-61 PMCID:PMC2795094

[2] Forero-Torres A.Bendamustine in non-hodgkin lymphoma: the double-agent that came from the cold war..Clin Lymphoma Myeloma2007;8:S13-7

[3] Leoni LM,Reifert J.Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents..Clin Cancer Res2008;14:309-17

[4] Weidmann E,Rost A.Bendamustine is effective in relapsed or refractory aggressive non-Hodgkin’s lymphoma..Ann Oncol2002;13:1285-9

[5] Miller KD,Mariotto AB.Cancer treatment and survivorship statistics, 2019..CA Cancer J Clin2019;69:363-85

[6] Friedberg JW.Relapsed/refractory diffuse large B-cell lymphoma..Hematology2011;2011:498-505

[7] Fields PA.Treatment of the elderly patient with diffuse large B cell lymphoma..Br J Haematol2012;157:159-70

[8] Arcari A,Spina M.Safety and efficacy of rituximab plus bendamustine in relapsed or refractory diffuse large B-cell lymphoma patients: an Italian retrospective multicenter study..Leuk Lymphoma2016;57:1823-30

[9] Jantunen E,Rambaldi A.Autologous stem cell transplantation in elderly patients (>=60 years) with diffuse large B-cell lymphoma: an analysis based on data in the European blood and marrow transplantation registry..Haematologica2008;93:1837-42

[10] Merchionne F,Gaudio F.Bendamustine plus rituximab for relapsed or refractory diffuse large B cell lymphoma: a retrospective analysis..Leuk Res2014;38:1446-50

[11] Hong JY,Suh C.Bendamustine plus rituximab for relapsed or refractory diffuse large B cell lymphoma: a multicenter retrospective analysis..Ann Hematol2018;97:1437-43

[12] Weidmann E,Fauth F.Phase II study of bendamustine in combination with rituximab as first-line treatment in patients 80 years or older with aggressive B-cell lymphomas..Ann Oncol2011;22:1839-44

[13] Ohmachi K,Uchida T.Multicenter phase II study of bendamustine plus rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma..J Clin Oncol2013;31:2103-9

[14] Vacirca JL,Tabbara IA.Bendamustine combined with rituximab for patients with relapsed or refractory diffuse large B cell lymphoma..Ann Hematol2014;93:403-9 PMCID:PMC3918114

[15] Park SI,Olajide O.A phase II trial of bendamustine in combination with rituximab in older patients with previously untreated diffuse large B-cell lymphoma..Br J Haematol2016;175:281-9 PMCID:PMC5063684

[16] Hitz F,Pabst T.Rituximab, bendamustine and lenalidomide in patients with aggressive B-cell lymphoma not eligible for anthracycline-based therapy or intensive salvage chemotherapy - SAKK 38/08..Br J Haematol2016;174:255-63

[17] Storti S,Pesce EA.Rituximab plus bendamustine as front-line treatment in frail elderly (>70 years) patients with diffuse large B-cell non-Hodgkin lymphoma: a phase II multicenter study of the Fondazione Italiana Linfomi..Haematologica2018;103:1345-50 PMCID:PMC6068040

[18] Sehn LH,Flowers CR.Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma..J Clin Oncol2020;38:155-65 PMCID:PMC7032881

[19] Rajkumar SV.Multiple myeloma: every year a new standard?.Hematol Oncol2019;37:62-5 PMCID:PMC6570407

[20] Matsui W,Wang Q.Characterization of clonogenic multiple myeloma cells..Blood2004;103:2332-6 PMCID:PMC3311914

[21] Nunnelee J,Benson DM.Improvement in survival of multiple myeloma patients: a long-term institutional experience..Blood2019;134:4573

[22] Thorsteinsdottir S,Landgren O.Dramatically improved survival in multiple myeloma patients in the recent decade: results from a Swedish population-based study..Haematologica2018;103:e412-5 PMCID:PMC6119139

[23] Pönisch W,Merkle K.Treatment of bendamustine and prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with Melphalan and Prednisone-a r..J Cancer Res Clin Oncol2006;132:205-12

[24] Gentile M,Recchia AG.Bendamustine in multiple myeloma..Eur J Haematol2015;95:377-88

[25] Offidani M,Maracci L.Efficacy and tolerability of bendamustine, bortezomib and dexamethasone in patients with relapsed-refractory multiple myeloma: a phase II study..Blood Cancer J2013;3:e162-9 PMCID:PMC3880441

[26] Mateos MV,Rosinol L.Bendamustine, bortezomib and prednisone for the treatment of newly diagnosed multiple myeloma patients: results of a prospective phase 2 Spanish/Pethema trial..Haematologica2015;100:1096-102 PMCID:PMC5004426

[27] Mey UJM,Schwarb H.Bendamustine, lenalidomide and dexamethasone (BRd) has high activity as 2nd-line therapy for relapsed and refractory multiple myeloma - a phase II trial..Br J Haematol2017;176:770-82

[28] Ludwig H,Leitgeb C.Bendamustine-bortezomib-dexamethasone is an active and well-tolerated regimen in patients with relapsed or refractory multiple myeloma..Blood2014;123:985-91 PMCID:PMC3924931

[29] Michael M,Bölke E.Bendamustine in patients with relapsed or refractory multiple myeloma..Eur J Med Res2010;15:13 PMCID:PMC3351842

[30] Swerdlow SH,Pileri SA.The 2016 revision of the World Health Organization classification of lymphoid neoplasms..Blood2016;127:2375-90 PMCID:PMC4874220

[31] Alizadeh AA,Eisen MB.Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling..Nature2000;403:503-11

[32] Bergsagel PL,Zhan F.Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma..Blood2005;106:296-303 PMCID:PMC1895118

[33] Dybkær K,Falgreen S.Diffuse large B-cell lymphoma classification system that associates normal B-cell subset phenotypes with prognosis..J Clin Oncol2015;33:1379-88 PMCID:PMC4397280

[34] Bødker JS,Schmitz A.A multiple myeloma classification system that associates normal B-cell subset phenotypes with prognosis..Blood Adv2018;2:2400-11 PMCID:PMC6156884

[35] Falgreen S,Young KH.Predicting response to multidrug regimens in cancer patients using cell line experiments and regularised regression models..BMC Cancer2015;15:1-15 PMCID:PMC4396063

[36] Falgreen S,Bødker JS.Exposure time independent summary statistics for assessment of drug dependent cell line growth inhibition..BMC Bioinformatics2014;15:168 PMCID:PMC4127655

[37] Bøgsted M,Wardell CP.Wallace GR.Proof of the concept to use a malignant B cell line drug screen strategy for identification and weight of melphalan resistance genes in multiple myeloma..PLoS One2013;8:e83252 PMCID:PMC3869769

[38] Laursen MB,Bødker JS.Human B-cell cancer cell lines as a preclinical model for studies of drug effect in diffuse large B-cell lymphoma and multiple myeloma..Exp Hematol2014;42:927-38

[39] Due H,Young KH,Dybkær K.MicroRNAs associated to single drug components of R-CHOP identifies diffuse large B-cell lymphoma patients with poor outcome and adds prognostic value to the international prognostic index..BMC Cancer2020;20:237 PMCID:PMC7082970

[40] Boegsted M,Fogd K.Cheriyath V.Generation of a predictive melphalan resistance index by drug screen of B-cell cancer cell lines..PLoS One2011;6:e19322 PMCID:PMC3084810

[41] Michaelsen TY,Brøndum RF.A B-cell-associated gene signature classification of diffuse large B-cell lymphoma by NanoString technology..Blood Adv2018;2:1542-6 PMCID:PMC6039667

[42] Visco C,Xu-Monette ZY.Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortiu..Leukemia2012;26:2103-13 PMCID:PMC3637886

[43] Lenz G,Dave SS.Stromal gene signatures in large-B-cell lymphomas..N Engl J Med2008;359:2313-23

[44] Monti S,Takeyama K.Integrative analysis reveals an outcome-associated and targetable pattern of p53 and cell cycle deregulation in diffuse large B cell lymphoma..Cancer Cell2012;22:359-72 PMCID:PMC3778921

[45] Broyl A,Lokhorst H.Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients..Blood2010;116:2543-53

[46] Dickens NJ,Leone PE.Homozygous deletion mapping in myeloma samples identifies genes and an expression signature relevant to pathogenesis and outcome..Clin Cancer Res2010;16:1856-64 PMCID:PMC2841345

[47] Shi L,Jones WD.The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models..Nat Biotechnol2010;28:827-38 PMCID:PMC3315840

[48] R Core TeamR: a language and environment for statistical computing. [Internet].2020;Vienna, Austria

[49] Emerson JW,Schloerke B.The generalized pairs plot..J Comput Graph Stat2013;22:79-91

[50] McCall MN,Irizarry RA.Frozen robust multiarray analysis (fRMA)..Biostatistics2010;11:242-53 PMCID:PMC2830579

[51] Friedman J,Tibshirani R.Regularization paths for generalized linear models via coordinate descent..J Stat Softw2010;33:7-10 PMCID:PMC2929880

[52] Kassambara A, Kosinski M, Biecek P, Fabian S. Survminer: drawing survival curves using “ggplot2” version 0.4.8. CRAN. 2020; (version 0.4.8). Available from: https://rdrr.io/cran/survminer/. [Last accessed on 12 Nov 2020]

[53] Zhang J,Love CL.Genetic heterogeneity of diffuse large B-cell lymphoma..Proc Natl Acad Sci2013;110:1398-403 PMCID:PMC3557051

[54] Munshi NC.Genomics in multiple myeloma..Clin Cancer Res2011;17:1234-42 PMCID:PMC3783001

[55] Bogeljić Patekar M.Bendamustine: an old drug in the new era for patients with non-hodgkin lymphomas and chronic lymphocytic leukemia..Acta Clin Croat2018;57:542-53 PMCID:PMC6536274

[56] Zeremski V,Kahl C.Is bendamustine-rituximab a reasonable treatment in selected older patients with diffuse large B cell lymphoma? Results from a multicentre, retrospective study..Ann Hematol2019;98:2729-37

[57] Kost SEF,LaBossière É.Cross-resistance and synergy with bendamustine in chronic lymphocytic leukemia..Leuk Res2016;50:63-71

[58] Hiraoka N,Yamauchi T.Akagi T.Purine analog-like properties of bendamustine underlie rapid activation of DNA damage response and synergistic effects with pyrimidine analogues in lymphoid malignancies..PLoS One2014;9:e90675 PMCID:PMC3953125

[59] Palmer AC,Sorger PK.A curative combination cancer therapy achieves high fractional cell killing through low cross-resistance and drug additivity..Elife2019;8:189-91 PMCID:PMC6897534

[60] Niu N.In vitro human cell line models to predict clinical response to anticancer drugs..Pharmacogenomics2015;16:273-85 PMCID:PMC4358765

[61] Quentmeier H,Dirks WG.The LL-100 panel: 100 cell lines for blood cancer studies..Sci Rep2019;9:1-14 PMCID:PMC6547646

[62] Pallasch CP,Braun CJ.Sensitizing protective tumor microenvironments to antibody-mediated therapy..Cell2014;156:590-602 PMCID:PMC3975171